Through studies in human hepatoma cell lines, clinical liver cancer specimens, human hepatoma model and patient-derived tumor xenograft model, we demonstrated that OA remarkably decreased PTB, resulting in HNF-4α activation and hepatoma differentiation. The gene discussed is HNF4A; the disease is hepatocellular carcinoma.